A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:11
|
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
    Terry, Rachael L.
    Meyran, Deborah
    Fleuren, Emmy D. G.
    Mayoh, Chelsea
    Zhu, Joe
    Omer, Natacha
    Ziegler, David S.
    Haber, Michelle
    Darcy, Phillip K.
    Trapani, Joseph A.
    Neeson, Paul J.
    Ekert, Paul G.
    CANCERS, 2021, 13 (18)
  • [42] Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy
    McGrath, Kyle
    Dotti, Gianpietro
    HUMAN GENE THERAPY, 2021, 32 (3-4) : 150 - 157
  • [43] Prospects of chimeric antigen receptor T cell therapy in ovarian cancer
    Jindal, Vishal
    Arora, Ena
    Gupta, Sorab
    Lal, Amos
    Masab, Muhammad
    Potdar, Rashmika
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [44] Chimeric antigen receptor T‑cell therapy—a hematological success story
    Wohlfarth P.
    Worel N.
    Hopfinger G.
    memo - Magazine of European Medical Oncology, 2018, 11 (2) : 116 - 121
  • [45] Advance in chimeric antigen receptor T therapy in autoimmune diseases
    Ji, Xiaolan
    Sun, Yunfan
    Xie, Yuyang
    Gao, Jianling
    Zhang, Ji
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [46] Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme
    Jindal, Vishal
    MOLECULAR NEUROBIOLOGY, 2018, 55 (11) : 8236 - 8242
  • [47] Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
    Timmers, Marijke
    Roex, Gils
    Wang, Yuedi
    Campillo-Davo, Diana
    Van Tendeloo, Viggo F., I
    Chu, Yiwei
    Berneman, Zwi N.
    Luo, Feifei
    Van Acker, Heleen H.
    Anguille, Sebastien
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [48] Chimeric antigen receptor T cells march into T cell malignancies
    Tang, Jie
    Zhao, Xudong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 13459 - 13475
  • [49] Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
    Stock, Sophia
    Kluever, Anna-Kristina
    Endres, Stefan
    Kobold, Sebastian
    BIOMEDICINES, 2022, 10 (02)
  • [50] T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
    De Bousser, Elien
    Callewaert, Nico
    Festjens, Nele
    CANCERS, 2021, 13 (23)